ERBB2 and adenocarcinoma: In a phase II clinical trial, KN026 showed favorable efficacy in patients with HER2-overexpressing G/GEJ adenocarcinoma with an objective response rate (ORR) of 55.6%; common adverse events included liver dysfunction and rash [61].